

# Michele Senni

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/240386/michele-senni-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

159  
papers

10,214  
citations

45  
h-index

99  
g-index

184  
ext. papers

15,870  
ext. citations

6.6  
avg, IF

6.05  
L-index

#	Paper	IF	Citations
159	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1413-1424	59.2	1099
158	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , <b>2021</b> , 42, 3599-3726	9.5	875
157	Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. <i>Circulation</i> , <b>1998</b> , 98, 2282-9	16.7	757
156	Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1609-1620	59.2	705
155	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. <i>European Heart Journal</i> , <b>2012</b> , 33, 1750-7	9.5	508
154	Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. <i>Circulation</i> , <b>2015</b> , 131, 54-61	16.7	430
153	Congestive heart failure in the community: trends in incidence and survival in a 10-year period. <i>Archives of Internal Medicine</i> , <b>1999</b> , 159, 29-34		253
152	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , <b>2014</b> , 35, 2797-815	9.5	231
151	Heart failure with preserved systolic function. A different natural history?. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 38, 1277-82	15.1	222
150	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 97-112	7.9	213
149	Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 136-45	7.9	190
148	Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. <i>Circulation</i> , <b>2012</b> , 125, 2639-48	16.7	158
147	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 487-496	7.9	139
146	Renal Effects and Associated Outcomes During Angiotensin-Nepriylsin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 489-498	7.9	138
145	Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). <i>American Heart Journal</i> , <b>2002</b> , 143, 45-55	4.9	138
144	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 556-569	15.1	135
143	Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1193-1203	12.3	135

142	Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 473-81	7.6	131
141	Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis: Multicenter Lombardy Registry. <i>Circulation</i> , <b>2018</b> , 138, 1088-1099	16.7	127
140	Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. <i>Journal of Cardiac Failure</i> , <b>2002</b> , 8, 279-87	3.3	122
139	Use of echocardiography in the management of congestive heart failure in the community. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 33, 164-70	15.1	121
138	Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 998-1007	12.3	114
137	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	109
136	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 995-1006	16.2	107
135	Prediction of right ventricular failure after ventricular assist device implant: systematic review and meta-analysis of observational studies. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 926-946	12.3	104
134	Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 1208-17	12.3	93
133	Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1687-96	15.1	90
132	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , <b>2016</b> , 37, 3167-3174	7.4	88
131	Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2059-2071	15.1	87
130	Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. <i>International Journal of Cardiology</i> , <b>2013</b> , 163, 206-11	3.2	85
129	Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1257-1266	12.3	76
128	In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. <i>International Journal of Cardiology</i> , <b>2014</b> , 173, 163-9	3.2	76
127	Left ventricular systolic and diastolic function after pericardiectomy in patients with constrictive pericarditis: Doppler echocardiographic findings and correlation with clinical status. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 33, 1182-8	15.1	76
126	Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis(I): Meta-Analysis Global Group in Chronic heart failure (MAGGIC). <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 1139-46	12.3	74
125	Nepriylsin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 710-717	12.3	71

124	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , <b>2015</b> , 36, 434-9	9.5	66
123	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1066-74	12.3	62
122	A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , <b>2012</b> , 33, 2080-7	9.5	60
121	End-systolic pressure/volume relationship during dobutamine stress echo: a prognostically useful non-invasive index of left ventricular contractility. <i>European Heart Journal</i> , <b>2005</b> , 26, 2404-12	9.5	60
120	Incremental Value of Gait Speed in Predicting Prognosis of Older Adults With Heart Failure: Insights From the IMAGE-HF Study. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 289-98	7.9	59
119	Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1231-9	12.3	59
118	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 54-65	12.3	57
117	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , <b>2014</b> , 35, 3442-51	9.5	54
116	Fibrinogen is an independent marker for thoracic aortic atherosclerosis. <i>American Journal of Cardiology</i> , <b>1998</b> , 81, 321-6	3	54
115	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , <b>2022</b> , 24, 4-131	12.3	50
114	A novel prognostic index to determine the impact of cardiac conditions and co-morbidities on one-year outcome in patients with heart failure. <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 1076-82	3	44
113	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , <b>2015</b> , 36, 1106-14	9.5	37
112	Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 491-500	12.3	37
111	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	36
110	Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 1713-21	3	35
109	Congestive heart failure in elderly patients. <i>Mayo Clinic Proceedings</i> , <b>1997</b> , 72, 453-60	6.4	35
108	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1596-1604	12.3	35
107	Prognostic scores in heart failure - Critical appraisal and practical use. <i>International Journal of Cardiology</i> , <b>2015</b> , 188, 1-9	3.2	33

106	Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. <i>International Journal of Cardiology</i> , <b>2015</b> , 199, 319-25	3.2	33
105	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , <b>2017</b> , 57, 440-451	2.9	33
104	Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 272-82	7	33
103	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , <b>2020</b> , 142, 1236-1245	16.7	32
102	Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 303-312	12.3	31
101	Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 327-336	3.7	30
100	Analysis of circumferential and longitudinal left ventricular systolic function in patients with non-ischemic chronic heart failure and preserved ejection fraction (from the CARRY-IN-HFpEF study). <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 383-9	3	29
99	Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 790-6 <sup>3</sup>		28
98	Temporal trends in survival and hospitalizations in outpatients with chronic systolic heart failure in 1995 and 1999. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 270-8	3.3	28
97	Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). <i>Circulation: Cardiovascular Interventions</i> , <b>2017</b> , 10,	6	23
96	Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e013441	6	23
95	Restrictive mitral valve annuloplasty versus mitral valve replacement for functional ischemic mitral regurgitation: an exercise echocardiographic study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2014</b> , 148, 447-53.e2	1.5	22
94	Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta-analysis report. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1220-7	12.3	22
93	Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure. <i>International Journal of Cardiology</i> , <b>2018</b> , 253, 97-104	3.2	21
92	Treatment with inotropes and related prognosis in acute heart failure: contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry. <i>Journal of Heart and Lung Transplantation</i> , <b>2014</b> , 33, 1056-65	5.8	21
91	Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH). <i>ESC Heart Failure</i> , <b>2018</b> , 5, 830-841	3.7	20
90	Baseline characteristics of patients in the Reduction of Events with Darbeoetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 334-41	12.3	20
89	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 514-522	12.3	20

88	Lessons learned in acute heart failure. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 630-641	12.3	19
87	Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1426-1433	12.3	19
86	Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 3691-7	3.2	19
85	The 30-day metric in acute heart failure revisited: data from IN-HF Outcome, an Italian nationwide cardiology registry. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1032-41	12.3	19
84	Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. <i>International Journal of Cardiology</i> , <b>2018</b> , 264, 118-123	3.2	19
83	Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives. <i>International Journal of Cardiology</i> , <b>2019</b> , 281, 158-165	3.2	18
82	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1065-1075	12.3	17
81	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 281-291	12.3	17
80	Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease. <i>Nature Reviews Cardiology</i> , <b>2017</b> , 14, 102-112	14.8	17
79	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. <i>International Journal of Cardiology</i> , <b>2018</b> , 266, 187-192	3.2	16
78	Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients. <i>Vascular Pharmacology</i> , <b>2016</b> , 80, 85-90	5.9	16
77	Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 423-31	7	16
76	Prevention of left ventricular remodelling after acute myocardial infarction: an update. <i>Recent Patents on Cardiovascular Drug Discovery</i> , <b>2010</b> , 5, 196-207		16
75	Sacubitril/valsartan (LCZ696) for the treatment of heart failure. <i>Expert Review of Cardiovascular Therapy</i> , <b>2016</b> , 14, 145-53	2.5	15
74	Determinants of functional capacity after mitral valve annuloplasty or replacement for ischemic mitral regurgitation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2015</b> , 149, 1595-603	1.5	15
73	Images in cardiovascular medicine. Bacterial pericarditis due to <i>Providencia stuartii</i> : an atypical case of relapsing pericarditis. <i>Circulation</i> , <b>2010</b> , 122, e401-3	16.7	15
72	The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels. <i>Clinical Cardiology</i> , <b>1997</b> , 20, 767-72	3.3	15
71	Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , <b>2016</b> , 28, 320-328	1.7	15

70	Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 760-3	12.3	14
69	Surgical ventricular reverse remodeling in severe ischemic dilated cardiomyopathy: the relevance of the left ventricular equator as a prognostic factor. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2006</b> , 131, 357-63	1.5	14
68	Aortic valve disease with severe ventricular dysfunction: stentless valve for better recovery. <i>Annals of Thoracic Surgery</i> , <b>2002</b> , 74, 2016-21	2.7	14
67	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , <b>2021</b> , 42, 3741-3752	9.5	13
66	Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis.. <i>Circulation</i> , <b>2022</b> , 145, 1123-1139	16.7	13
65	Novel approaches to the post-myocardial infarction/heart failure neural remodeling. <i>Heart Failure Reviews</i> , <b>2014</b> , 19, 611-9	5	12
64	Atrial fibrillation, cognitive impairment, frailty and disability in older heart failure patients. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17, 616-23	1.9	12
63	Successful treatment of subacute constrictive pericarditis with interleukin-1 receptor antagonist (anakinra). <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, 294-5	2.2	12
62	Addressing the Heterogeneity of Heart Failure in Future Randomized Trials. <i>Current Heart Failure Reports</i> , <b>2017</b> , 14, 197-202	2.8	11
61	N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. <i>European Journal of Preventive Cardiology</i> , <b>2018</b> , 25, 889-895 <sup>9</sup>	3.9	11
60	Monitoring of biomarkers in heart failure. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, M5-M8	1.5	11
59	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , <b>2015</b> , 13, 799-809	2.5	10
58	Dose-dependent efficacy of $\beta$ -blocker in patients with chronic heart failure and atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2018</b> , 273, 141-146	3.2	10
57	How patients with heart failure are managed in Italy. <i>European Journal of Heart Failure</i> , <b>2001</b> , 3, 257-60	12.3	10
56	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 1919-1929	27.4	10
55	NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 822-833	7.9	10
54	Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial. <i>Clinical Pharmacology in Drug Development</i> , <b>2019</b> , 8, 942-951	2.3	10
53	Exercise Hemodynamic and Functional Capacity After Mitral Valve Replacement in Patients With Ischemic Mitral Regurgitation: A Comparison of Mechanical Versus Biological Prostheses. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e004056	7.6	10

52	Low incidence of gastrointestinal bleeding and pump thrombosis in patients receiving the INCOR LVAD system in the long-term follow-up. <i>International Journal of Artificial Organs</i> , <b>2015</b> , 38, 542-7	1.9	9
51	Transcatheter treatment of chronic mitral regurgitation with the MitraClip system: an Italian consensus statement. <i>Journal of Cardiovascular Medicine</i> , <b>2014</b> , 15, 173-88	1.9	9
50	Cardiac resynchronization in combination with beta blocker treatment in advanced chronic heart failure (CARIBE-HF): the results of the CARIBE-HF study. <i>Acta Cardiologica</i> , <b>2011</b> , 66, 573-80	0.9	9
49	Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1540-1548	12.3	9
48	Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs. <i>International Journal of Cardiology</i> , <b>2017</b> , 226, 136-140	3.2	8
47	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 768-776	3.8	8
46	Beneficial effects of adaptive servo-ventilation on natriuretic peptides and diastolic function in acute heart failure patients with preserved ejection fraction and sleep-disordered breathing. <i>Sleep and Breathing</i> , <b>2019</b> , 23, 287-291	3.1	8
45	Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 743-50	3	8
44	Left main stem patch plasty and aortic root homograft in Takayasu's disease. <i>Annals of Thoracic Surgery</i> , <b>2004</b> , 77, 314-7	2.7	8
43	Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1551-1553	12.3	7
42	Haemodynamics of Heart Failure With Preserved Ejection Fraction: A Clinical Perspective. <i>Cardiac Failure Review</i> , <b>2016</b> , 2, 102-105	4.2	7
41	Usefulness of regional right ventricular and right atrial strain for prediction of early and late right ventricular failure following a left ventricular assist device implant: A machine learning approach. <i>International Journal of Artificial Organs</i> , <b>2020</b> , 43, 297-314	1.9	7
40	Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 185-91	12.3	7
39	Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19. <i>Atherosclerosis</i> , <b>2021</b> , 328, 136-143	3.1	7
38	Natriuretic peptides and the Framingham risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 5093-5	3.2	6
37	Multiplane transoesophageal echocardiographic detection of thoracic aortic plaque is a marker for coronary artery disease in women. <i>International Journal of Cardiology</i> , <b>1997</b> , 61, 269-75	3.2	6
36	Implantation of an elastic ring at equator of the left ventricle influences cardiac mechanics in experimental acute ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 1791-8	15.1	6
35	Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition. <i>International Journal of Cardiology</i> , <b>2017</b> , 226, 132-135	3.2	5



34	A multidisciplinary consensus document on follow-up strategies for patients treated with percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , <b>2015</b> , 85, E129-39 <sup>2-7</sup>	5
33	Toward the development of a fully elastic mitral ring: preliminary, acute, in vivo evaluation of biomechanical behavior. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2009</b> , 137, 174-9	1.5 5
32	Sacubitril/valsartan: from a large clinical trial to clinical practice. <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19, 473-479	1.9 5
31	Transvenous pacing in pediatric patients with bipolar lumenless lead: Ten-year clinical experience. <i>International Journal of Cardiology</i> , <b>2018</b> , 255, 45-49	3.2 4
30	Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. <i>International Journal of Cardiology</i> , <b>2017</b> , 248, 414-420	3.2 4
29	Global Longitudinal Strain in master athletes and in hypertensive patients with the same degree of septal thickness. <i>Scandinavian Journal of Medicine and Science in Sports</i> , <b>2017</b> , 27, 1411-1416	4.6 4
28	Ranolazine in heart failure with preserved left ventricular ejection fraction and microvascular dysfunction: case report and literature review. <i>Journal of Clinical Pharmacology</i> , <b>2013</b> , 53, 665-9	2.9 4
27	Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. <i>Handbook of Experimental Pharmacology</i> , <b>2017</b> , 243, 79-108	3.2 4
26	Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials. <i>Cardiology</i> , <b>2015</b> , 130, 69-81	1.6 3
25	Cavotricuspid isthmus ablation and subcutaneous monitoring device implantation in a 2-year-old baby with 2 SCN5A mutations, sinus node dysfunction, atrial flutter recurrences, and drug induced long-QT syndrome: a tricky case of pediatric overlap syndrome?. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2015</b> , 26, 346-9	2.7 3
24	Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487319899618	3.9 3
23	Reasons why patients suffering from chronic heart failure at very high risk for death survive. <i>International Journal of Cardiology</i> , <b>2014</b> , 177, 213-8	3.2 3
22	An intriguing case report of functional mitral regurgitation treated with MitraClip. <i>Medicine (United States)</i> , <b>2015</b> , 94, e608	1.8 3
21	Use of implantable cardioverter defibrillator and cardiac resynchronization therapy: an Italian survey study on 220 cardiology departments. <i>Journal of Cardiovascular Medicine</i> , <b>2012</b> , 13, 675-83	1.9 3
20	The Titan can help titin: from micro to macro myocardial elasticity. <i>Journal of Cardiovascular Medicine</i> , <b>2006</b> , 7, 153-8	1.9 3
19	Hemodynamic arterial changes in heart failure: a proposed new paradigm of "Heart and Vessels Failure (HVF)". <i>Minerva Cardiology and Angiology</i> , <b>2021</b> ,	2.4 3
18	Treating Patients Following Hospitalisation for Acute Decompensated Heart Failure: An Insight into Reducing Early Rehospitalisations. <i>Cardiac Failure Review</i> , <b>2019</b> , 5, 78-82	4.2 2
17	Cardiogenic shock: How to overcome a clinical dilemma. Unmet needs in Emergency medicine. <i>International Journal of Cardiology</i> , <b>2015</b> , 186, 19-21	3.2 2

16	Medical treatment of end-stage heart failure. <i>Cardiovascular Drugs and Therapy</i> , <b>1996</b> , 10 Suppl 2, 617-22,9	2
15	Risk stratifying asymptomatic left ventricular systolic dysfunction in the community: beyond left ventricular ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2020</b> , 21, 1405-1411	4.1 2
14	Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. <i>Progress in Cardiovascular Diseases</i> , <b>2021</b> , 67, 89-97	8.5 2
13	Reasons why patients suffering from chronic heart failure at very low risk for mortality die. <i>International Journal of Cardiology</i> , <b>2016</b> , 223, 947-952	3.2 2
12	Incremental prognostic value of echocardiography of left ventricular remodeling and diastolic function in STICH trial. <i>Cardiovascular Ultrasound</i> , <b>2020</b> , 18, 17	2.4 1
11	Clinical application of personalized medicine: heart failure with preserved left ventricular ejection fraction. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, L124-L128	1.5 1
10	Renin profiling predicts neurohormonal response to sacubitril/valsartan. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 719-724	3.4 1
9	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 627-635	7.9 1
8	External closed-circuit cooling system for management of patients after device implantation: A feasibility study. <i>International Journal of Cardiology</i> , <b>2017</b> , 241, 235-237	3.2 0
7	Echocardiographic outflow pump ramp test in centrifugal-flow left ventricular assist device. <i>International Journal of Artificial Organs</i> , <b>2017</b> , 0	1.9 0
6	Clinical correlates of autonomic response during tilting test in hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , <b>2017</b> , 18, 255-261	1.9
5	Prognostic scores: one fits all?. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 588	12.3
4	Is 3D Echo With Ramp Test Indicated in Detecting Blood Flow Obstructions in HeartWare LVAD?. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2126-2127	15.1
3	How should I treat a challenging case of MitraClip implantation?. <i>EuroIntervention</i> , <b>2014</b> , 10, 887-90	3.1
2	Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 2326-2329	3.9
1	Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , <b>2021</b> , 7, e06	4.2